The 16 most recent market catalysts affecting $CMND, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 11, 2026
Corporate Catalyst
Neutral
Impact 75
Clearmind Medicine Announces First Two Alcohol Use Disorder Patients Enrolled At Hadassah Medical Center In Ongoing CMND-100 Trial
The enrollment of the first two patients in Clearmind Medicine's CMND-100 trial for Alcohol Use Disorder is a crucial corporate catalyst. This marks the transition from preclinical…
Sep 4, 2026
Corporate Catalyst
Neutral
Impact 75
Clearmind shares are trading lower. The company announced a definitive agreement to acquire a 51% controlling stake in Charging Robotics for an aggregate purchase price of $2.5 million.
This acquisition represents a significant corporate catalyst for Clearmind, indicating a strategic shift or expansion. The immediate negative market reaction suggests investor appr…
Sep 4, 2026
Corporate Catalyst
Bearish
Impact 85
Clearmind Medicine Stock Slides Friday: What's Happening?
Clearmind Medicine, traditionally a biotech focused on psychedelic compounds, is making a significant strategic pivot by acquiring a 51% stake in Charging Robotics, an electric veh…
Sep 4, 2026
Corporate Catalyst
Neutral
Impact 65
Clearmind Medicine Announces $2.5M Deal To Acquire 51% Stake In EV Wireless Charging Firm Charging Robotics, Plus $1.5M Loan At 4%; Expects Close Week Of September 7
This headline indicates a significant strategic move by Clearmind Medicine, a biotechnology company, into the electric vehicle wireless charging sector. While the deal size is rela…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 75
Clearmind Medicine Says DSMB Unanimously Approved Advancing Phase 1/2 Trial Of CMND-100 To Parts B And C In Alcohol Use Disorder Patients And Healthy Participants
The unanimous approval to advance the Phase 1/2 trial of CMND-100 is a significant positive catalyst for Clearmind Medicine. It de-risks the drug's development pathway to some exte…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 65
Clearmind Medicine Says Permeation Study Shows Intranasal MEAI Reached 97.35% Cumulative Permeation At 180 Minutes vs. 98.34% For Conventional Formulation
This news is a positive development for Clearmind Medicine as it validates the efficacy of their intranasal drug delivery system for MEAI. Achieving comparable permeation to conven…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Clearmind Medicine Announces DSMB Approval To Advance Phase 1/2 Trial Of CMND-100 Into Parts B And C, Marking First Dosing In Alcohol Use Disorder Patients
This news is a significant positive catalyst for Clearmind Medicine (CMND) as it marks the first dosing of CMND-100 in Alcohol Use Disorder patients within a Phase 1/2 trial. Advan…
Aug 3, 2026
Corporate Catalyst
Bearish
Impact 65
Clearmind Medicine shares are trading lower after the company signed a non-binding LoI to acquire a 51% stake in a company making intelligent EV wireless charging solutions for automated parking systems and autonomous mobile platforms.
The headline indicates a corporate catalyst for Clearmind Medicine (CMND). The negative market reaction suggests investor apprehension regarding the company's strategic direction, …
Aug 3, 2026
Corporate Catalyst
Neutral
Impact 65
Clearmind Medicine Announces Non-Binding Letter Of Intent To Acquire 51% Stake In Unnamed EV Wireless Charging Company For $2.5M Plus $1.5M Loan At 4% Interest
This headline indicates a significant strategic shift for Clearmind Medicine, a biotechnology company, into the electric vehicle wireless charging sector. While the deal size ($2.5…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 75
Clearmind Medicine Announces Safety Results From Part A Of Its Ongoing FDA-regulated Phase I/II Clinical Trial Evaluating CMND-100; All 24 Participants Enrolled Across Four Ascending-Dose Cohorts Successfully Completed Treatment
Clearmind Medicine reported that its lead drug candidate, CMND-100, successfully completed Part A of its FDA-regulated Phase I/II clinical trial, meeting its primary endpoint of sa…
Jul 20, 2026
Corporate Catalyst
Neutral
Impact 55
Clearmind Medicine Files Hong Kong Patent Application For Innovative Psychedelic Compounds For Treatment Of Post-Traumatic Stress Disorder
Clearmind Medicine has filed a patent application in Hong Kong for novel psychedelic compounds for PTSD treatment, leveraging its exclusive global licensing agreement with Yissum. …
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 55
Clearmind Medicine Announces Ex Vivo Mucoadhesion Results For Intranasal MEAI; New Formulation Demonstrated Markedly Improved Nasal Residence Characteristics Compared With Standard MEAI Solution
Clearmind Medicine has released promising ex vivo study results showing that its new intranasal MEAI formulation has markedly improved nasal residence characteristics. This is sign…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 75
CMND stock has given up its prior gain. Clearmind Medicine shares were trading higher after the company announced an update based on their "hands-on" experience from the CMND-100 trial.
The headline points to a classic 'buy the rumor, sell the news' scenario or a re-evaluation of the trial's actual significance by the market. While the 'hands-on' experience from t…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 75
Clearmind Medicine shares are trading higher after the company announced an update based on their "hands-on" experience from the CMND-100 trial.
This headline signals a significant positive development for Clearmind Medicine, as 'hands-on experience' from a trial often implies qualitative data or early efficacy signals that…
Jul 13, 2026
Corporate Catalyst
Bearish
Impact 60
CORRECTION: Clearmind Medicine shares are trading lower.
The headline directly points to a negative event for Clearmind Medicine (CMND), indicating a decline in its share price. This is a corporate-specific catalyst, likely driven by int…
Jul 13, 2026
Corporate Catalyst
Neutral
Impact 65
Clearmind Medicine Announces CMND‑100, Current Phase I/IIa Trial Demonstrates Impression To Treat Alcohol Use Disorder
Clearmind Medicine's 8-K filing discloses an update from its ongoing Phase I/IIa clinical trial for CMND-100, a potential treatment for Alcohol Use Disorder. The key takeaway is th…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.